Abstract
Leucocytes accumulate at sites of inflammation and microbial infection in response to locally produced chemotactic factors. N-formylpeptides produced by Gram negative bacteria were among the first chemotactic factors structurally defined which signal through G protein-coupled formylpeptide receptor (FPR) and FPR-like 1 (FPRL1) expressed by phagocytic leukocytes in human and in mouse homogogues mFPR and mFPR2. During the past few years, a number of pathogen- and host-derived agonists/antagonists for FPR, FPRL1 and another FPR variant FPR-like 2 (FPRL2) have been identified. Activation of formylpeptide receptors (FPRs) in phagocytic leukocytes by agonists results in increased cell chemotaxis, phagocytosis, and release of pro-inflammatory mediators. Peptide agonists for FPRs have also been shown to possess immune adjuvant activity when injected in mice. In addition, FPR aberrantly expressed on highly malignant human glioblastoma cells promotes tumor cell migration, proliferation and production of vascular endothelial growth factor in response to agonists released by necrotic tumor cells. Therefore, formylpeptide receptor ligands, by interacting with FPRs, play important roles in host defense and in the rapid progression of human glioblastoma.
Keywords: Formylpeptide receptors, agonist, antagonist, inflammation, infection, tumor
Protein & Peptide Letters
Title: Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Volume: 14 Issue: 9
Author(s): Yingying Le, Ji Ming Wang, Xiaolei Liu, Yan Kong, Xinwei Hou, Lingfei Ruan and Haiwei Mou
Affiliation:
Keywords: Formylpeptide receptors, agonist, antagonist, inflammation, infection, tumor
Abstract: Leucocytes accumulate at sites of inflammation and microbial infection in response to locally produced chemotactic factors. N-formylpeptides produced by Gram negative bacteria were among the first chemotactic factors structurally defined which signal through G protein-coupled formylpeptide receptor (FPR) and FPR-like 1 (FPRL1) expressed by phagocytic leukocytes in human and in mouse homogogues mFPR and mFPR2. During the past few years, a number of pathogen- and host-derived agonists/antagonists for FPR, FPRL1 and another FPR variant FPR-like 2 (FPRL2) have been identified. Activation of formylpeptide receptors (FPRs) in phagocytic leukocytes by agonists results in increased cell chemotaxis, phagocytosis, and release of pro-inflammatory mediators. Peptide agonists for FPRs have also been shown to possess immune adjuvant activity when injected in mice. In addition, FPR aberrantly expressed on highly malignant human glioblastoma cells promotes tumor cell migration, proliferation and production of vascular endothelial growth factor in response to agonists released by necrotic tumor cells. Therefore, formylpeptide receptor ligands, by interacting with FPRs, play important roles in host defense and in the rapid progression of human glioblastoma.
Export Options
About this article
Cite this article as:
Le Yingying, Wang Ming Ji, Liu Xiaolei, Kong Yan, Hou Xinwei, Ruan Lingfei and Mou Haiwei, Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors, Protein & Peptide Letters 2007; 14 (9) . https://dx.doi.org/10.2174/092986607782110211
DOI https://dx.doi.org/10.2174/092986607782110211 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Current Computer-Aided Drug Design Chemical Variability and Antioxidant Activities of the Essential Oils of the Aerial Parts of Ammoides verticillata and the Roots of Carthamus caeruleus and their Synergistic Effect in Combination
Combinatorial Chemistry & High Throughput Screening Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Imaging Findings of Primary Non-functioning Hepatic Paraganglioma: A Case Report
Current Medical Imaging Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism The Plasma Levels of hsa-miR-19b-3p, hsa-miR-125b-5p, and hsamiR- 320c in Patients with Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS)
MicroRNA Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters